Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries.

childhood malignant bone tumors cohort study late effects somatic disease survivorship

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Sep 2021
Historique:
received: 10 08 2021
revised: 02 09 2021
accepted: 03 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Survivors of malignant bone tumors in childhood are at risk of long-term adverse health effects. We comprehensively reviewed cases of somatic diseases that required a hospital contact in survivors of osteosarcoma and Ewing sarcoma. In a population-based cohort study, 620 five-year survivors of osteosarcoma (n = 440) or Ewing sarcoma (n = 180), diagnosed before the age of 20 years in Denmark, Finland, Iceland, and Sweden during 1943-2008, were followed in the national hospital registers. Overall rates of hospital contacts for any somatic disease and for 12 main diagnostic groups and 120 specific disease categories were compared with those in a matched comparison cohort (n = 3049) randomly selected from the national population registers. The rate of hospital contact for any somatic disease was 80% higher in survivors of malignant bone tumors than in comparisons and remained elevated up to 30 years after diagnosis. The rate of hospital contacts was higher after Ewing sarcoma (rate ratio (RR) 2.24; 95% confidence interval (CI) 1.76-2.85) than after osteosarcoma (RR 1.67; 95% CI 1.41-1.98). Elevated rates were observed for 11 main diagnostic groups, including infections, second malignant neoplasms, and diseases of the skin, bones, and circulatory, digestive, endocrine, and urinary systems. Survivors of malignant bone tumors in childhood are at increased risk of somatic diseases many years after diagnosis. This comprehensive study contributes new insight into the risk of late effects in survivors of osteosarcoma and Ewing sarcoma, which is an essential basis for optimal patient counseling and follow-up care.

Identifiants

pubmed: 34572734
pii: cancers13184505
doi: 10.3390/cancers13184505
pmc: PMC8467516
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Børnecancerfonden
ID : 2014-48; 2015-32
Organisme : Barncancerfonden
ID : PR2014-0121
Organisme : Kræftens Bekæmpelse
ID : A7588

Références

J Clin Oncol. 1996 Oct;14(10):2818-25
pubmed: 8874344
J Natl Cancer Inst. 2010 Aug 18;102(16):1272-83
pubmed: 20656964
Cancer. 2017 Jul 1;123(13):2551-2560
pubmed: 28222219
Br J Cancer. 2015 Jun 9;112(12):1857-65
pubmed: 25989269
Pediatr Blood Cancer. 2012 Jul 15;59(1):126-32
pubmed: 22180128
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Eur J Cancer. 2008 May;44(7):983-91
pubmed: 18353632
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Cancer. 2012 Oct 15;118(20):5050-9
pubmed: 22415578
Scand J Public Health. 2012 Aug;40(6):505-15
pubmed: 22899561
J Pediatr Hematol Oncol. 1997 May-Jun;19(3):220-5
pubmed: 9201144
PLoS Med. 2017 May 9;14(5):e1002296
pubmed: 28486495
J Pediatr Hematol Oncol. 2006 Dec;28(12):774-80
pubmed: 17164644
Int J Epidemiol. 2015 Feb;44(1):324-33
pubmed: 25501468
Cancer. 2011 Feb 1;117(3):625-34
pubmed: 20922787
Cancer. 2005 Apr 1;103(7):1457-67
pubmed: 15712273
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1280-9
pubmed: 24925676
Circulation. 2013 Oct 22;128(17):1927-95
pubmed: 24081971
Int J Cancer. 1987 Nov 15;40(5):620-4
pubmed: 3679589
J Pediatr Hematol Oncol. 2015 Apr;37(3):170-4
pubmed: 25089605
Br J Cancer. 2014 Mar 4;110(5):1342-50
pubmed: 24366296
Blood. 2007 Jan 1;109(1):46-51
pubmed: 16985182
J Natl Cancer Inst. 2010 Jul 21;102(14):1083-95
pubmed: 20634481
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
Am J Clin Oncol. 2017 Aug;40(4):423-428
pubmed: 25599318
Curr Opin Pediatr. 2009 Jun;21(3):365-72
pubmed: 19421061
J Clin Oncol. 2015 Sep 20;33(27):3036-46
pubmed: 26304893
Cancer. 2008 Nov 1;113(9):2597-604
pubmed: 18823030
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Pediatr Blood Cancer. 2015 Dec;62(12):2204-10
pubmed: 26193842
Cancer. 2002 Oct 15;95(8):1728-34
pubmed: 12365021
J Natl Cancer Inst. 2009 Jun 3;101(11):806-13
pubmed: 19470947

Auteurs

Camilla Pedersen (C)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.

Catherine Rechnitzer (C)

Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, 2100 Copenhagen, Denmark.

Elisabeth Anne Wreford Andersen (EAW)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.

Line Kenborg (L)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.

Filippa Nyboe Norsker (FN)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.

Andrea Bautz (A)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.

Thomas Baad-Hansen (T)

Department of Orthopedic Surgery, Sarcoma Centre of Aarhus University Hospital, 8200 Aarhus, Denmark.

Laufey Tryggvadottir (L)

The Icelandic Cancer Registry, 105 Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, 102 Reykjavik, Iceland.

Laura-Maria Madanat-Harjuoja (LM)

The Finnish Cancer Registry, 00130 Helsinki, Finland.

Anna Sällfors Holmqvist (AS)

Department of Clinical Sciences Lund, Lund University, 222 41 Lund, Sweden.
Department of Pediatric Hematology and Oncology, Skane University Hospital, 221 85 Lund, Sweden.

Lars Hjorth (L)

Department of Clinical Sciences Lund, Lund University, 222 41 Lund, Sweden.
Department of Pediatric Hematology and Oncology, Skane University Hospital, 221 85 Lund, Sweden.

Henrik Hasle (H)

Department of Pediatrics, Aarhus University Hospital, 8200 Aarhus, Denmark.

Jeanette Falck Winther (JF)

Danish Cancer Society Research Center, 2100 Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, 8200 Aarhus, Denmark.

Classifications MeSH